The global digital phenotyping market is expected to rise from USD 2.0 billion in 2026 and is projected to reach USD 7.1 billion by 2040, growing at a CAGR of 9.5% over the forecast period 2026 to 2040, driven by regulated remote digital endpoints and AI-enabled multimodal capacity monitoring. Based on Geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 12.4% CAGR through 2040, driven by healthcare digitalization and trial localization.

The global RNAi therapeutics market, valued at USD 2.9 billion in 2025, is projected to reach USD 3.6 billion in 2026 and USD 9.1 billion by 2035, representing a CAGR of 10.8% during the forecast period 2026 to 2035. With respect to route of administration, intravenous administration accounts for the highest share, capturing 45% of the current market. In June 2026, Alnylam Pharmaceuticals and Inceptive Nucleics announced a strategic AI-driven collaboration valued at up to USD 2 billion, includin...

The global AI-powered pharmacovigilance market is expected to rise from USD 0.83 billion in 2026 and is projected to reach USD 5.59 billion by 2040, growing at a CAGR of 14.6% over the forecast period 2026 to 2040, driven by rising safety-data complexity. Based on deployment model, cloud-based solutions are both dominant and fastest-growing, holding 58.0% share in 2026 and expanding at 16.1% CAGR through 2040, driven by scalable global safety operations.

The global healthcare interoperability solutions market is expected to rise from USD 5.8 billion in 2026 to reach USD 31.5 billion by 2040, growing at a CAGR of 12.8% over the forecast period 2026 to 2040, driven by regulatory interoperability mandates and cloud-native FHIR adoption. Long-term growth will accelerate as cloud deployment, semantic interoperability, and FHIR APIs reshape procurement through 2040. Oracle Health received TEFCA QHIN designation in November 2025 and linked customer onb...

The global Duchenne muscular dystrophy market reached USD 5.2 billion in 2026 and is projected to reach USD 28.7 billion by 2040, growing at a CAGR of 13.0% over the forecast period 2026 to 2040, driven by mutation-targeted therapies, gene transfer adoption, and broader rare-disease reimbursement. Based on therapy class, gene therapies capture 34.0% market share in 2026, whereas cell therapies register a 28.4% CAGR through 2040, driven by late-stage cardiac and skeletal-muscle programs. Based on...

The global PERK inhibitors market is envisaged to rise from USD 46.0 million in 2026 and is projected to reach USD 450.0 million by 2040, growing at a CAGR of 17.7% over the forecast period 2026 to 2040, driven by Phase 1b oncology combination development and research-enablement demand. Based on product / offering type, therapeutic drug candidates is both the dominant and fastest-growing category, holding 34.0% share in 2026 and expanding at 21.3% CAGR through 2040, driven by oncology pipeline v...

The global cloud based drug discovery platforms market, valued at USD 3.7 billion in 2025, is projected to reach USD 4.2 billion in 2026 and USD 11.4 billion by 2035, representing a CAGR of 11.7% during the forecast period 2026 to 2035. Cloud based drug discovery platforms are centralized, internet-hosted software ecosystems that provide scalable computing power, data storage, and advanced analytics tools to accelerate the discovery of new therapeutic compounds. According to our projections, Nor...

The Europe non-viral transfection reagents market, valued at USD 0.22 billion in 2025, is projected to reach USD 0.24 billion in 2026 and USD 0.40 billion by 2035, representing a CAGR of 5.7% during the forecast period 2026-2035. Non-viral transfection reagents refer to chemical or physical delivery systems that introduce nucleic acids, including DNA, RNA, mRNA, siRNA, and gene editing components, into target cells without relying on viral vectors. In addition, rising investment in nucleic acid-...

The global CRISPR based therapeutics market, valued at USD 0.1 billion in 2025, is projected to reach USD 0.2 billion in 2026 and USD 6.3 billion by 2035, with a CAGR of 43.8% during the forecast period 2026 to 2035. The CRISPR domain has evolved from basic scientific research into an important area of advanced therapeutics. Notably, the in vivo therapies segment is expected to grow at a significant pace during the forecast period due to rapid advancements in targeted gene-editing delivery techn...

The global hospital command center market is expected to rise from USD 2.40 billion in 2026 to reach USD 10.10 billion by 2040, growing at a CAGR of 10.8% over the forecast period 2026 to 2040, driven by hospital-wide demand for real-time capacity orchestration. Based on Geography, North America captures 42.0% market share in 2026, whereas Asia-Pacific registers a 13.5% CAGR through 2040, supported by digital hospital infrastructure expansion.

The global RNAi technology market, valued at USD 3.3 billion in 2025, is projected to reach USD 3.8 billion in 2026 and USD 12.5 billion by 2035, representing a CAGR of 14.0% during the forecast period 2026 to 2035. RNA interference (RNAi) technology is a gene-silencing approach that selectively suppresses disease-causing genes at the messenger RNA (mRNA) level. Initially developed as a research tool, RNAi has evolved into a clinically validated therapeutic platform. Currently, the siRNA segment...

The global AI in clinical trials market, valued at USD 3.48 billion in 2025, is projected to reach USD 3.96 billion in 2026 and USD 11.61 billion by 2035, representing a CAGR of 12.7% during the forecast period 2026 to 2035. Based on the deployment mode, cloud-based AI solutions capture the largest share (around 75%) of the current market, and the trend is unlikely to change in the future. In terms of therapeutic areas, oncological disorders are expected to hold the largest market share (more th...

The global battery-free implants market is expected to rise from USD 9.3 billion in 2026 to reach USD 83.4 billion by 2040, growing at a CAGR of 17.0% over the forecast period 2026 to 2040, driven by wireless power transfer, miniaturization, and fewer replacement surgeries. Battery-free implant development is shifting from isolated passive sensors toward programmable therapeutic and diagnostic platforms. Near-field inductive coupling still holds 32.0% of 2026 revenue because mature coils support...

The global surgical robots market, valued at USD 9.8 billion in 2025, is projected to reach USD 10.6 billion in 2026 and USD 22.9 billion by 2035, with a 8.9% CAGR during the forecast period 2026 to 2035. In terms of geography, North America captures the majority of the market share.

The global cell therapy manufacturing market, valued at USD 6.3 billion in 2025, is projected to reach USD 7.2 billion in 2026 and USD 14.0 billion by 2035, representing a CAGR of 7.7% during the forecast period 2026 to 2035. Researchers are investigating more than 1,000 cell and gene therapy candidates for the treatment of a myriad of disease indications. Amongst these, around 45 cell-based therapies have already been approved by various regulatory authorities across the globe. Further, several...

The global next generation contact lenses and visual prostheses market, valued at USD 0.36 billion in 2024, is projected to reach USD 0.60 billion in 2025 and USD 16.97 billion by 2035, representing a CAGR of 39.7% during the forecast period. It is worth highlighting here that there is a rapid increase witnessed in the number of blind and partially sighted individuals. According to the National Eye Institute, nearly 1.3 million people are blind, while 2.9 million individuals have poor vision, in...

The global CAR-T cell therapy market, valued at USD 6.1 billion in 2025, is projected to reach USD 7.7 billion in 2026 and USD 15.6 billion by 2035, with a 8.1% CAGR during the forecast period 2026 to 2035. In terms of target antigen, the CD19 targeting therapies segment holds the highest share (more than 65%) of the market. With regards to target indication, the multiple myeloma segment dominates the global market with close to 30% market share. In terms of geographical regions, North America c...

The global neural implants market is expected to rise from USD 7.4 billion in 2026 to reach USD 29.2 billion by 2040, growing at a CAGR of 10.3% over the forecast period 2026 to 2040, driven by rising neurological disease burdens and adaptive closed-loop stimulation. Adaptive sensing and closed-loop stimulation are shifting neural implants from fixed-output devices toward responsive, personalized therapy. Spinal cord stimulation still anchors demand, holding 45.5% share in 2026, while deep brain...

The global hospital at home market reached USD 29.0 billion in 2026 and is projected to reach USD 199.1 billion by 2040, growing at a CAGR of 14.8% over the forecast period 2026 to 2040, driven by hospital capacity constraints. Based on geography, North America captures 46.0% market share in 2026, whereas Asia-Pacific registers a 17.3% CAGR through 2040, driven by virtual hospital scale-up. Based on component / offering, Services capture 54.0% market share in 2026, whereas Software platforms reg...

The global Home Sleep Apnea Testing Market reached USD 1.90 billion in 2026 and is projected to reach USD 6.40 billion by 2040, growing at a CAGR of 9.1% over the forecast period 2026 to 2040, driven by untreated OSA prevalence, payer acceptance of HSAT, and AI-enabled multi-night diagnostics. Based on geography, North America captures 44.0% market share in 2026, whereas Asia-Pacific registers an 11.3% CAGR through 2040, driven by diagnostic-access gaps and local device innovation. Untreated obs...